Format

Send to

Choose Destination
Curr Opin Pharmacol. 2015 Aug;23:68-73. doi: 10.1016/j.coph.2015.05.015. Epub 2015 Jun 10.

BRAF inhibitors: the current and the future.

Author information

1
Roche Innovation Center New York, 430 E. 29th Street, New York, NY 10016, United States. Electronic address: Weijiang.zhang@roche.com.

Abstract

The introduction of BRAF inhibitors (BRAFi), vemurafenib and dabrafenib, revolutionized BRAFV600-mutated metastatic melanoma treatment with improved response rate and overall survival compared to standard chemotherapy. However, the mechanism related cutaneous toxicity remains a concern. In addition, intrinsic and acquired resistance remain the key challenges in BRAFi therapy. Extensive efforts to elucidate the mechanisms have led to an improved understanding of disease biology and resulted in exploration of multiple new therapeutic options. While the future looks bright with multiple new therapeutic strategies in exploration and possible new generations of BRAFi, there are questions remaining to be answered to enable more efficient use of BRAFi in cancer therapy.

PMID:
26072431
DOI:
10.1016/j.coph.2015.05.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center